# Eli Lilly and Company (1876-)

> Prima azienda healthcare a raggiungere $1 trillion di market cap (Nov 2025), dominante nel mercato GLP-1 con Mounjaro e Zepbound - fondata da un colonnello della Guerra Civile, ora guidata dal network PhRMA-Business Roundtable

## Executive Summary

| Metrica | Valore |
|---------|--------|
| **Fondazione** | 10 maggio 1876 |
| **Sede** | Indianapolis, Indiana, USA |
| **Tipo** | Pharma |
| **Chairman & CEO** | David A. Ricks (2017-) |
| **Revenue 2025** | ~$63B |
| **Market Cap** | **$1 trillion** (Nov 2025) |
| **Dipendenti** | ~43,000 |
| **Status** | active |

---

## Glossario

| Termine | Definizione |
|---------|-------------|
| GLP-1 | Glucagon-like peptide-1 agonists (farmaci per diabete/obesita') |
| Tirzepatide | Principio attivo di Mounjaro e Zepbound |
| Lilly Endowment | Fondazione separata, $80B assets |

---

## Fondazione e Storia

| Dato | Dettaglio |
|------|-----------|
| **Fondazione** | 10 maggio 1876 |
| **Fondatore** | Col. Eli Lilly (veterano Guerra Civile) |
| **Sede originale** | 15 West Pearl Street, Indianapolis |
| **Dipendenti iniziali** | 4 (Eli, figlio Josiah 14 anni, 2 altri) |
| **Mission** | "High-quality, effective medications backed by science" |

### Il Colonnello Eli Lilly

| Dato | Dettaglio |
|------|-----------|
| **Nascita** | 8 luglio 1838, Baltimore, Maryland |
| **Morte** | 6 giugno 1898, Indianapolis |
| **Educazione** | Indiana Asbury College (ora DePauw) |
| **Guerra Civile** | Colonnello Union Army, prigioniero di guerra |
| **Innovazioni** | Capsule di gelatina, aromi alla frutta |

### Timeline Storica

| Anno | Evento |
|------|--------|
| **1876** | Fondazione da Col. Eli Lilly |
| **1881** | Trasferimento sede attuale; incorporazione |
| **1898** | Morte fondatore; Josiah K. Lilly Sr. diventa presidente |
| **1923** | Primo produttore commerciale di insulina |
| **1937** | Fondazione Lilly Endowment |
| **1952** | Introduzione eritromicina |
| **1988** | Lancio Prozac (fluoxetina) |
| **2017** | David Ricks diventa CEO |
| **2022** | Approvazione Mounjaro (tirzepatide) |
| **2023** | Approvazione Zepbound (obesita') |
| **Nov 2025** | **$1 trillion market cap** (primo healthcare) |

---

## Struttura e Governance

### Leadership Attuale

| Ruolo | Nome | Dal |
|-------|------|-----|
| **Chairman & CEO** | [David A. Ricks](../persons/david-ricks.md) | 2017 |
| **Lead Independent Director** | [Juan R. Luciano](../persons/juan-luciano.md) | 2019 |

### Board of Directors (2025)

| Nome | Ruolo Principale | Note |
|------|------------------|------|
| [David A. Ricks](../persons/david-ricks.md) | Chairman & CEO Eli Lilly | - |
| [Juan R. Luciano](../persons/juan-luciano.md) | Chairman & CEO ADM | Lead Independent Director |
| [Jon Moeller](../persons/jon-moeller.md) | Chairman & CEO P&G | - |
| [William G. Kaelin Jr.](../persons/william-kaelin.md) | Professor HMS | **Nobel Prize Medicine 2019** |
| Katherine Baicker | Provost U. Chicago | - |
| Ralph Alvarez | Operating Partner Advent | - |
| J. Erik Fyrwald | CEO IFF | - |
| Mary Lynne Hedley | Fellow Broad Institute | - |
| Jamere Jackson | CFO AutoZone | - |
| Kimberly H. Johnson | COO T. Rowe Price | - |

### CEO Storici

| Nome | Periodo | Note |
|------|---------|------|
| Col. Eli Lilly | 1876-1898 | Fondatore |
| Josiah K. Lilly Sr. | 1898-1932 | Figlio |
| Eli Lilly Jr. | 1932-1948 | Nipote |
| John K. Lilly | 1948-1953 | - |
| Eugene N. Beesley | 1953-1961 | Primo CEO non-famiglia |
| ... | ... | ... |
| John C. Lechleiter | 2008-2016 | - |
| **David A. Ricks** | 2017- | Attuale |

---

## Prodotti Chiave

### GLP-1: Il Business da $19B

| Prodotto | Indicazione | Revenue 9M 2025 | Market Share |
|----------|-------------|-----------------|--------------|
| **Mounjaro** | Diabete tipo 2 | ~$10B | 53% GLP-1 globale |
| **Zepbound** | Obesita' | ~$9B | Leader USA |
| **Combinato** | - | ~$19B | Supera Keytruda (Merck) |

### Pipeline e Aree Terapeutiche

| Area | % Revenue | Prodotti Chiave |
|------|-----------|-----------------|
| **Diabetes & Obesity** | >60% | Mounjaro, Zepbound |
| Oncology | - | Verzenio (breast cancer) |
| Immunology | - | Taltz, Olumiant |
| Neuroscience | - | Kisunla/Donanemab (Alzheimer) |

### Milestone Storici

| Anno | Prodotto | Impatto |
|------|----------|---------|
| **1923** | Insulina | Primo produttore commerciale |
| **1988** | Prozac | Rivoluzione antidepressivi |
| **2022** | Mounjaro | Game-changer diabete |
| **2023** | Zepbound | Primo competitor serio a Ozempic |

---

## Network e Connessioni

### Mappa delle Appartenenze CEO

```
                     DAVID RICKS
                          |
      +-------------------+-------------------+
      |                   |                   |
      v                   v                   v
  ELI LILLY           LOBBY/INDUSTRY      BUSINESS
      |                   |                   |
 ┌────┴────┐         ┌────┴────┐         ┌────┴────┐
 |         |         |         |         |         |
Chairman  CEO      PhRMA    IFPMA      Business   Adobe
& CEO            (ex-Chair)  (CEO SC)  Roundtable (board)
2017-            2020-22
```

### Affiliazioni CEO David Ricks

| Organizzazione | Ruolo | Periodo |
|----------------|-------|---------|
| [Eli Lilly](../pharma/eli-lilly.md) | Chairman & CEO | 2017- |
| [PhRMA](../agency/phrma.md) | Board Chairman | 2020-2022 |
| [Business Roundtable](../think-tank/business-roundtable.md) | Member | - |
| IFPMA | CEO Steering Committee | - |
| Business Council | Member | - |
| Adobe | Board | - |

### Board Cross-Links

| Board Member | Altre Affiliazioni |
|--------------|-------------------|
| Juan Luciano | ADM (CEO), Lead Independent |
| Jon Moeller | P&G (CEO) |
| William Kaelin | Harvard Medical School, Nobel 2019 |
| Kimberly Johnson | T. Rowe Price (COO) |

---

## Lilly Endowment

### Fondazione Separata

| Dato | Dettaglio |
|------|-----------|
| **Fondazione** | 1937 |
| **Fondatori** | J.K. Lilly Sr., Eli Jr., Josiah Jr. |
| **Assets** | ~$80B (2024) |
| **Grants totali** | $15.21B (87 anni) |
| **Focus** | Religion, Education, Community (Indiana) |

### Relazione con Azienda

```
ELI LILLY AND COMPANY (Pharma)
         |
         | (stock ownership storico)
         v
LILLY ENDOWMENT (Foundation)
         |
         +---> Entita' SEPARATE
         +---> Governance INDIPENDENTE
         +---> Focus: Indiana, Religion, Education
```

**Nota**: La fondazione e' legalmente separata dall'azienda. Condividono solo origine storica e stock.

### Donazioni Recenti

| Anno | Importo | Destinazione |
|------|---------|--------------|
| 2024 | $100M | Purdue University |
| 2024 | $100M | UNCF (HBCUs) |
| 2024 | $809M | Grants religiosi |

---

## La Dinastia Lilly

### Quattro Generazioni

| Gen | Nome | Ruolo | Periodo |
|-----|------|-------|---------|
| 1 | Col. Eli Lilly | Fondatore, CEO | 1876-1898 |
| 2 | Josiah K. Lilly Sr. | CEO | 1898-1932 |
| 3 | Eli Lilly Jr. | CEO, Fondatore Endowment | 1932-1948 |
| 3 | Josiah K. Lilly Jr. | Fondatore Endowment | - |
| 4 | - | Nessun ruolo operativo | - |

**Pattern**: Come molte dinastie pharma USA, la famiglia Lilly e' uscita dalla gestione operativa ma mantiene influenza attraverso la fondazione.

---

## Competizione GLP-1

### Eli Lilly vs Novo Nordisk

| Metrica | Eli Lilly | Novo Nordisk |
|---------|-----------|--------------|
| Prodotti | Mounjaro, Zepbound | Ozempic, Wegovy |
| Principio attivo | Tirzepatide | Semaglutide |
| Market share 2025 | **53%** | 47% |
| Efficacia perdita peso | ~20% | ~15% |

**Sorpasso 2025**: Lilly ha superato Novo per la prima volta nel mercato GLP-1 globale.

---

## Connessioni PowerLink

### Organizzazioni

| Entita' | Connessione |
|---------|-------------|
| [PhRMA](../agency/phrma.md) | Member; Ricks ex-Chairman |
| [Business Roundtable](../think-tank/business-roundtable.md) | Ricks member |
| [Lilly Endowment](../foundation/lilly-endowment.md) | Fondazione separata |
| [Harvard Medical School](../company/harvard-medical-school.md) | Kaelin (board) professor |
| [Novo Nordisk](../pharma/novo-nordisk.md) | Competitor GLP-1 |

### Persone

| Persona | Relazione |
|---------|-----------|
| [David Ricks](../persons/david-ricks.md) | Chairman & CEO |
| [William Kaelin](../persons/william-kaelin.md) | Board, Nobel 2019 |
| [Juan Luciano](../persons/juan-luciano.md) | Lead Independent Director |
| [Jon Moeller](../persons/jon-moeller.md) | Board, CEO P&G |

### Famiglia

| Persona | Relazione |
|---------|-----------|
| Col. Eli Lilly | Fondatore (Gen 1) |
| Josiah K. Lilly Sr. | CEO (Gen 2) |
| Eli Lilly Jr. | CEO, Endowment founder (Gen 3) |

---

## Pattern Identificati

### 1. Pharma → $1 Trillion

```
1876: Fondazione ($0)
      |
      v
2017: Ricks CEO (~$70B)
      |
      v
2022: Mounjaro approval
      |
      v
2023: Zepbound approval
      |
      v
Nov 2025: $1 TRILLION
         (14x in 8 anni)
```

### 2. Famiglia → Fondazione → Influenza

```
FAMIGLIA LILLY
      |
      +---> Exit operativo (post-Gen 3)
      |
      +---> Lilly Endowment ($80B)
                  |
                  +---> Indiana community
                  +---> Religion (maggior donatore USA)
                  +---> Education
```

### 3. CEO Network Hub

David Ricks connette:
- **Lobby**: PhRMA (ex-Chair), IFPMA
- **Business**: Business Roundtable, Business Council
- **Tech**: Adobe (board)
- **Local**: Central Indiana Corporate Partnership

---

## Fonti

### Ufficiali
- [Eli Lilly - About](https://www.lilly.com/about)
- [Eli Lilly - Leadership](https://www.lilly.com/about/leadership)
- [Eli Lilly - Board](https://www.lilly.com/leadership/board-of-directors)
- [Eli Lilly - History](https://www.lilly.com/about/history)
- [Eli Lilly - Investor Relations](https://investor.lilly.com/)

### Lilly Endowment
- [Lilly Endowment](https://lillyendowment.org/)
- [Lilly Endowment - History](https://lillyendowment.org/about/history-and-founders/)

### Wikipedia
- [Wikipedia - Eli Lilly and Company](https://en.wikipedia.org/wiki/Eli_Lilly_and_Company)
- [Wikipedia - Eli Lilly (founder)](https://en.wikipedia.org/wiki/Eli_Lilly)
- [Wikipedia - David A. Ricks](https://en.wikipedia.org/wiki/David_A._Ricks)
- [Wikipedia - Lilly Endowment](https://en.wikipedia.org/wiki/Lilly_Endowment)

### News/Analisi
- [BioPharma Dive - $1 Trillion](https://www.biopharmadive.com/news/eli-lilly-1-trillion-pharmaceutical-market-value-obesity/721819/)
- [Chief Executive - Ricks CEO of Year](https://chiefexecutive.net/ceo-of-the-year-a-conversation-with-eli-lillys-dave-ricks/)
- [PhRMA - Ricks Chairman](https://phrma.org/Press-Release/Eli-Lilly-and-Company-Chairman-and-CEO-David-Ricks-Becomes-PhRMA-Board-Chairman)
- [Business Roundtable - Ricks](https://www.businessroundtable.org/members/david-a.-ricks)

### Famiglia/Storia
- [Philanthropy Roundtable - Eli Lilly](https://www.philanthropyroundtable.org/hall-of-fame/eli-lilly/)
- [Indiana Historical Society - Eli Lilly](https://indianahistory.org/stories/you-are-there-eli-lilly-at-the-beginning/)
- [Encyclopedia of Indianapolis](https://indyencyclopedia.org/eli-lilly-and-company/)

---

*Ultimo aggiornamento: Dicembre 2025*
